First FDA approval for thrombocytopenia in chronic liver disease

The US Food and Drug Administration on Monday approved Doptelet (avatrombopag) tablets to treat low blood platelet count, or thrombocytopenia, in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

This is the first drug approved by the FDA for this use, and comes after the agency completed its Priority Review of Doptelet, which was developed by US company Dova Pharmaceuticals (Nasdaq: DOVA).

"Given our extensive preparations to date, we are positioned to launch Doptelet in June with our full complement of sales, marketing, and reimbursement support resources"